Avantor, Inc. (NYSE: AVTR), a leading global provider of mission-critical products and services to customers in the life sciences, advanced technologies and applied materials industries, today announced that it has entered into a multi-year supply and services agreement with Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide

"We have seen firsthand that Avantor is a terrific partner that brings diverse capabilities and expertise across modalities and geographies, which is essential to meeting global health needs," said Alessandro Maselli, President and Chief Executive Officer, Catalent. "We look forward to deepening our work with the Avantor team to bring current and novel treatments to patients around the world." 

"Catalent has built tremendous global capabilities and a reputation as a trusted collaborator to pharma, biotech and consumer health partners throughout the development and production lifecycle," said Michael Stubblefield, President and CEO of Avantor. "We are pleased to expand our support for Catalent and enable efficiencies to accelerate science for their customers around the globe."

This expanded relationship reflects Avantor's long history of providing customers with choice, reliability and innovative solutions.